Compare XBIT & BDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | BDL |
|---|---|---|
| Founded | 2005 | 1959 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 63.2M |
| IPO Year | 2015 | 1995 |
| Metric | XBIT | BDL |
|---|---|---|
| Price | $2.37 | $38.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 25.1K | 3.3K |
| Earning Date | 05-08-2026 | 05-18-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | N/A | ★ 49.72 |
| EPS | N/A | ★ 1.98 |
| Revenue | N/A | ★ $205,248,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.37 |
| Revenue Growth | N/A | ★ 8.99 |
| 52 Week Low | $2.09 | $26.33 |
| 52 Week High | $3.61 | $42.31 |
| Indicator | XBIT | BDL |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 68.08 |
| Support Level | $2.35 | $29.14 |
| Resistance Level | $2.41 | N/A |
| Average True Range (ATR) | 0.05 | 1.54 |
| MACD | 0.00 | 0.82 |
| Stochastic Oscillator | 40.79 | 89.52 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.